SOCIUM
AI-powered drug discovery targeting over 15 diseases, including oncology and rare diseases, using systems biology and machine learning.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$2.4m | Series B | ||
| Total Funding | 000k | ||
Related Content
SOCIUM Inc. is an AI-powered drug discovery and development company focused on creating first-in-class small molecules. The company operates in the pharmaceutical and biotechnology sectors, targeting over 15 diseases, including oncology and rare diseases. SOCIUM employs a systems biology approach, leveraging augmented intelligence and machine learning to profile entire diseases by analyzing various OMICS data, rather than hypothesizing disease mechanisms and focusing on a few related compounds.
SOCIUM's business model revolves around research and development (R&D) in drug discovery, aiming to address unmet medical needs. The company generates revenue through partnerships, licensing agreements, and potential future sales of developed drugs. SOCIUM serves pharmaceutical companies, healthcare providers, and patients who require innovative treatments for diseases with limited or ineffective existing therapies.
SOCIUM operates in a highly competitive market characterized by rapid technological advancements and significant R&D investments. The company differentiates itself through its unique AI-driven approach and its commitment to pioneering the future of drug discovery.
Keywords: AI-powered, drug discovery, small molecules, systems biology, machine learning, oncology, rare diseases, OMICS data, pharmaceutical, biotechnology.